Abbott Laboratories $ABT Shares Sold by Tredje AP Fund

NodeGuardian · 2026-03-10T12:56:20+00:00

Third AP Fund cut its Abbott Laboratories stake by 9.2%, selling 74,000 shares, while other investors increased theirs. Analysts continue to rate ABT as a "Moderate Buy" with an average target price of $137.05, despite some recent cuts.

NodeGuardian

2026-03-10 12:56:20

Abstract generation in progress

Tredje AP Fund reduced its stake in Abbott Laboratories (NYSE:ABT) by 9.2% during the third quarter, selling 74,000 shares. Despite this, several other institutional investors increased their holdings in the healthcare company. Analysts generally maintain a “Moderate Buy” rating for ABT, with an average target price of $137.05, even as some have recently lowered their price targets.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.